# Decoy Therapeutics Inc. (DCOY) · Edgar & Edgarette company card

> Decoy Therapeutics (DCOY) saw revenue fall 100% in FY2022 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 70.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1615219 · fiscal year ended 2022-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/DCOY) · [JSON](https://www.pops4.com/boards/company/DCOY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -696.3%) |
| Net margin | -Infinity% |
| Operating cash flow | −$18M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $12M |
| Long-term debt | — |
| Total assets | $15M |
| Total equity | $10M |
| Equity ÷ assets | 70.9% |
| Return on equity | -304.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Sound ship · one warning sign · operating cash flow was negative (-$4.8M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2022). Experience: revenue down 100.0% on the year; operating margin null, down from -696.3%. Soundness: equity 70.9% of assets, return on equity -304.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-01-02 ([filing](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000005/0001615219-26-000005-index.htm))
- Item 5.02 Director or officer change: 2, latest 2025-11-19 ([filing](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000168/0001615219-25-000168-index.htm))

## Recent filings

- S-1 · filed 2026-10-07 · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000119312526417053/0001193125-26-417053-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000019/0001615219-26-000019-index.htm)
- 8-K · filed 2026-09-15 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000016/0001615219-26-000016-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000119312526346852/0001193125-26-346852-index.htm)
- DEF 14A · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000119312526332762/0001193125-26-332762-index.htm)
- 8-K · filed 2026-07-15 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/0001193125-26-304949-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001615219.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1615219

## Cite

POPS4, Edgar & Edgarette: Decoy Therapeutics Inc. (DCOY) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/DCOY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2022, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.